FDA/CDC
-
FDA/CDC
FDA OKs IV Briviact for seizures in kids as young as 1 month
The approval marks the first time that the IV formulation will be available for children.
-
FDA/CDC
FDA okays new oral CGRP antagonist for migraine prevention
With this approval, neurologists will be able to choose from four monoclonal antibodies and two gepants for the preventive treatment of migraine...
-
FDA/CDC
FDA clears first mobile rapid test for concussion
Eye-Sync is a virtual reality eye-tracking platform that provides objective measurements to aid in the assessment of concussion.
Conference Coverage
-
Conference Coverage
Novel drug effective for essential tremor, but with significant side effects
Patients receiving the drug saw significant reduction in upper-limb tremors, but adverse events led many to discontinue treatment.
-
Conference Coverage
Worsening motor function tied to post COVID syndrome in Parkinson’s disease
About half of the study participants with Parkinson’s disease who developed post–COVID-19 syndrome experienced worsening motor symptoms and needed...
-
Conference Coverage
Is genetic testing valuable in the clinical management of epilepsy?
Positive findings from genetic testing helped guide clinical management in 50% of cases and improved patient outcomes in 75%.
-
Conference Coverage
Double antiglutamatergic therapy is ‘promising’ for super-refractory status epilepticus
The novelty of the new treatment approach is the duration of therapy as well as the dual antiglutamate drugs.
-
Conference Coverage
COVID-19 vaccination in MS: Lower response on certain medications
Currently approved COVID-19 vaccines appear safe in patients with MS and are effective in most patients.
-
Conference Coverage
In MS, baseline cortical lesions predict cognitive decline
Baseline MRI findings can inform cognitive monitoring over time.
-
Conference Coverage
Ublituximab improves functional MS score: New ULTIMATE analysis
Trial data are being used to support a recent approval application to the FDA for ublituximab to treat patients with relapsing remitting MS.
-
Conference Coverage
ECTRIMS/EAN statement on COVID-19 vaccination in patients with MS
The statement concludes that the COVID-19 vaccines that are currently available are safe for patients with MS.
-
Conference Coverage
Art therapy linked to slowed Parkinson’s progression
The positive effect of art therapy could be related to “activating the brain’s reward neural network,” said Dr. Iryna Khubetova.
-
Conference Coverage
Rituximab more effective than other MS treatments?
The risk for a first relapse was 6 times higher in patients receiving interferon beta or glatiramer acetate, compared with those receiving...
Latest News
-
Latest News
Scientists who unlocked secrets of pain sensation win nobel prize
“In our daily lives we take these sensations for granted, but how are nerve impulses initiated so that temperature and pressure can be perceived?...
-
From the Journals
Is AFib a stroke cause or innocent bystander? The debate continues
Many believe AFib is a risk marker for stroke, but new evidence suggests it may be a causal risk factor.
-
From the Journals
‘Fascinating’ link between Alzheimer’s and COVID-19
Study findings could lead to new treatment targets to slow progression and severity of both diseases.
News
-
News
ADHD med may reduce apathy in Alzheimer’s disease
Methylphenidate provides a “modest but potentially clinically significant benefit for patients and caregivers,” said Dr. Jacobo Mintzer and...